| Hepatitis B (HB), caused by hepatitis B virus (HBV), is a global health problem. Worldwide, an estimated 350 million people infected with the hepatitis B virus (HBV), and more than 120 million in China. Hepatitis B vaccine is the mainstay of hepatitis B prevention. However, there's still about 5-10% people are no response to hepatitis B vaccine inoculation.In order to enhance the immune responses to hepatitis B vaccine, immune co-enhancing molecule (ICEM) was designed by Bioinformatics and Immunology principle. ICEM-pBV220 plasmid was constructed and the recombinant protein was expressed in E.coli DH5asystem. ICEM was injected to Balb/c mice combined with HBV vaccine 4 times at intervals of twelve days. It was found that ICEM could significantly enhance the immune response to the HBV vaccine and the average antibody tirer was significantly higher than the control group. (p<0.01) Furthermore, ICEM increased Th2-biased immune response by inducing interleukin-4(IL-4) production. These results showed that ICEM combined with HBV vaccine could significantly enhance immune responses to HBV vaccine. |
PDF Full Text Request